HBIO Q3 2026 Revenue Grows 8% to $22.2 Million
Harvard Bioscience Inc reported third-quarter revenue of $22.2 million, up 8% year-over-year. The company reaffirmed full-year 2026 revenue growth guidance of 3-5% and reported an adjusted EBITDA of $1.8 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed